Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PMCB $0.155 + $0.0111
Major Paper Shows How Melligen Cell Line Derived from Human Liver Cells Can Reverse Diabetes
http://finance.yahoo.com/news/major-paper-shows-melligen-cell-120000285.html
PMCB $0.152 + $0.022
New Research Shows PharmaCyte Biotech's Melligen Cell Line Can Reverse Diabetes
http://finance.yahoo.com/news/research-shows-pharmacyte-biotechs-melligen-133000240.html
RGBP stock of the year potential (or of a lifetime).
$$COCP$$-They grow up so fast!
http://stockcharts.com/h-sc/ui?s=cocp
$ADMD - looking strong here going into FDA approval
It's ok - she's grandfathered in even though she graduated. Nice pick Joe!
Just realized COCP "graduated", it is no longer under a buck. Seems like only 6 months ago it was 40 cents....hey that is true!
COCP @$1.06. Presented today at Barclays Global Healthcare Conference. Looks to be very active in 2015/2016
$ADMD - on close watch here
Nice one Joe! Just wish I saw it a few weeks ago ;)
COCP Chart
http://stockcharts.com/h-sc/ui?s=cocp
Thanks basssque - will check the 2 out
$CVM $0.78
Just breaking out now on large blocks due to a new discovery!
Researchers discover genetic fingerprint of HPV virus in some head and neck cancers
http://www.healthcanal.com/cancers/59867-researchers-discover-genetic-fingerprint-of-hpv-virus-in-some-head-and-neck-cancers.html
With thanks from a friend of mine on another board (associated with another stock I am hold long-term) for pointing it out.
Wouldn't it be 'interesting' if Multikine was effective in treating a viral disease (HPV warts in HIV positive people), and if that same virus was in play as a potential cause of Head and Neck Cancer?
Hmmmmm,.....
Quote:A large US study (link is external) has pinpointed genetic errors that mark out head and neck cancers caused by the human papillomavirus (HPV).
"This important study greatly improves our understanding of the biology of head and neck cancer" - Professor Nick Coleman, Cancer Research UK
US scientists have combed the genetic code of head and neck cancers.
If confirmed in further studies this could be used to develop potential new treatments.
Head and neck cancers include tumours of the throat, mouth, nasal cavity, larynx, salivary gland among other tissues and organs.
Some are linked to tobacco or alcohol use, while others are caused by infection with HPV, more commonly associated with cervical cancers.
Rates of HPV-linked head and neck cancers are on the increase.
The US study, published in the journal Nature (link is external), was carried out as part of The Cancer Genome Atlas (link is external) (TCGA) project.
Using cutting-edge DNA analysis, the team found several similarities between the DNA from head and neck tumour cells and other cancer types - as well as new subtypes of smoking-related head and neck cancer.
The US team studied samples from 279 head and neck squamous cell carcinomas (HNSCC) from untreated patients, around eight in 10 of whom were smokers. Most of the samples were oral cavity cancers and larynx cancers (61 per cent and 26 per cent respectively).
The researchers found that specific alterations in genes called FGFR3 and PIK3CA – which produce important protein molecules that help cells grow – were common in many patients with HPV-related cancers.
These genes are also present in a wider set of faults found in smoking-related tumours.
But faults in the epidermal growth factor receptor (EGFR) gene, which produces another important growth molecule, were rare among HPV-positive cancers, despite being frequently altered in HPV-negative tumours.
Similarities between the DNA of head and neck tumours cells and other cancers - including squamous cell lung cancer, and cervical cancer - were also found, suggesting there may be common paths of cancer development – and potentially treatment.
Calling the study “important”, Professor Nick Coleman - a Cancer Research UK expert in HPV and cancer - went on to say: “It greatly improves our understanding of the biology of head and neck cancer, pinpointing crucial genetic differences between those tumours caused by HPV infection, and others linked with risk factors like smoking.
"HPV-linked head and neck cancers are becoming more common, and this study suggests that the virus may trigger a small number of genetic faults that are causing the disease. This opens up important new avenues of research, with the possibility of developing treatments targeted to these faults to help tackle head and neck cancer in the future."
Director of the National Human Genome Research Institute in the US, Dr Eric Green, said that the new findings “help establish a genomic map of various head and neck cancers, provide new insights into other similar cancers and may further our understanding of how viruses can impact disease.”
$GTHP $0.18
My Opinion
The PR below speaks for itself. The original due date based on the FDA 180 day deadline was January 24th.
If the FDA wasn't seriously considering approval they would have canned this by now.
There are only 59 million shares in the float, so it should move very well with approval. Any other information would be all speculation. But personally, I think it's possibly very explosive with approval.
They have been working on this product for 15 years, it will truly revolutionize OBGYN visits for women eliminating the Pap Smear. (ask your woman how much she loves having a Pap Smear and how much she would like a scanner that can detect precancerous cells up to 2 years earlier). One of these scanners in every OBGYN Office is a gold mine! It's already approved in other countries.
It traded up close to $2/share in 2011
This is my largest position in my whole portfolio and I have MANY positions right now. FYI and GLTA
Guided Therapeutics Provides an Update on FDA Review Time for LuViva® Advanced Cervical Scan
Date : 02/03/2015 @ 8:05AM
Source : Business Wire
Stock : Guided Therapeutics, Inc. (QB) (GTHP)
Quote : 0.193 0.0031 (1.63%) @ 9:58AM
Guided Therapeutics Provides an Update on FDA Review Time for LuViva® Advanced Cervical Scan
Print
Alert
Guided Therapeutics, Inc. (QB) (OTCBB:GTHP)
Intraday Stock Chart
Today : Tuesday 3 February 2015
Click Here for more Guided Therapeutics, Inc. (QB) Charts.
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the pre-market approval (PMA) application for the LuViva® Advanced Cervical Scan. The company has been in communication with the agency and is hoping to receive the agency’s decision within the next several weeks.
“We continue to believe our PMA amendment addressed the remaining questions the agency had and remain hopeful the FDA will find a pathway forward for LuViva,” said Gene Cartwright, Chief Executive Officer of Guided Therapeutics.
Mr. Cartwright added, “Importantly, the review timeline by the FDA does not impact the ability of our distributors to continue to sell LuViva internationally. We continue to see momentum building in the larger international market. We expect to see solid demand from Latin America, South Asia and Africa in 2015 where our distributors are working with federal and local governments for orders.”
The Company anticipates providing sales guidance for the upcoming year in March 2015 when it reports its results for the year ended December 31, 2014.
The Company currently has regulatory approval to sell LuViva in Europe with the Edition 3 CE mark, and has marketing approvals from COFEPRIS in Mexico, Health Canada and Singapore Health Sciences Authority, among others. Additionally, expansion efforts are ongoing in the Middle East, Asia and Latin America.
About LuViva® Advanced Cervical Scan
LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which may result in eliminating costly, painful and unnecessary additional testing. LuViva is intended for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. It has also been used in clinical studies in Turkey and Nigeria as a means to screen women for cervical cancer where the availability of infrastructure necessary for Pap and HPV testing is restricted. The device is used in conjunction with the LuViva® Cervical Guide single-use patient interface and calibration disposable.
About Guided Therapeutics
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com.
The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.
Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2013, and subsequent quarterly reports.
Guided Therapeutics
Bill Wells, 770-242-8723
or
Investor Relations:
Cameron Associates
Alison Ziegler, 212-554-5469
Some solid plays last 2 days, $RCHA & QMDT - both posting HUGE gains $$$. Time to get this board active again.
Could be a rocket launch today. Currently NVLX 0.232, up .035
Nice candle on Friday Joe
http://stockcharts.com/h-sc/ui?s=NVLX
Nuvilex (NVLX) achieves FDA ODD status for a treatment of pancreatic cancer
http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=457014
NVLX 12/16/14 - Shareholder Update on Recent Activities in the Areas of Cancer and Diabetes
SILVER SPRING, Md., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company providing cell solutions for the treatment of diseases, today announced a shareholder update on the Company's cancer and diabetes programs utilizing its Cell-in-a-Box(R) cellulose-based live cell encapsulation technology.
-The first preclinical study by TD2 in the U.S. that deals with the effectiveness of Nuvilex's pancreatic cancer treatment on the accumulation of malignant ascites fluid that is often associated with the growth of abdominal cancers, including pancreatic cancer, has been completed and positive results were obtained.
-Nuvilex has commenced the development of a clinical protocol for the planned Phase 2b clinical trial in pancreatic cancer.
-Applications have been submitted to drug regulatory authorities in the U.S., Europe and Australia to obtain Orphan Drug status for Nuvilex's pancreatic cancer treatment that combines Cell-in-a-Box(R) with low doses of the anticancer prodrug ifosfamide.
-Contracts have been executed with major institutions that will permit the development of a diabetes treatment that combines Cell-in-a-Box(R) with insulin-producing cells, and a Diabetes Consortium has been established to facilitate this important research.
-The live cell encapsulation facility in Thailand, where the Cell-in-a-Box(R) encapsulation will be done, has now officially opened and is an extremely important development as this facility is essential for all of Nuvilex's efforts in developing treatments for cancer and diabetes.
-Rapid progress is being achieved at the University of Northern Colorado in the pursuit of treatments for cancer that will combine cannabinoid-like compounds with the Cell-in-a-Box(R) technology.
"This is truly an exciting, important time for Nuvilex, and I wish to extend my sincere appreciation to our longstanding shareholders for their continued support during this transformational period of our growth," commented Kenneth L. Waggoner, Chief Executive Officer of Nuvilex.
An extensive update on Nuvilex's programs has been prepared and can be reviewed on the Nuvilex website at: http://www.nuvilex.com/shareholder-update-on-recent-activities-in-the-areas-of-cancer-and-diabetes
In CYTX for a nice starter, chart looks good and a lot of upside here
Thanks for the TA link. I have long thought I should know more about charting. In the mean time I use this site for dummies like me, seems to be refreshed with current data pretty often
http://www.barchart.com/quotes/stocks/NVLX
If you look lower right at "Support & Resistance" it indicates the trading points and often traders target (the triangle bit) for a stock with any volume. If you click the "more" in that same box you get a "longer" view of key price points of the stock of interest. Of course you can put in any stock name you want
Nice Free Slideshare on Technical Analysis
http://www.slideshare.net/BigTrends/the-technical-analysis-guidebook
AEMD- nice news this am
COCP - Cocrystal Pharma: Small Cap Company With Transformative Merger
http://seekingalpha.com/article/2715995-cocrystal-pharma-small-cap-company-with-transformative-merger
Same to you and the rest of the board readers. Should be some highly interesting developments in small biostocks on my radar soon
Happy Thanksgiving Everyone!
NVLX - Nuvilex Announces the Formation of a Diabetes Consortium for the Development of Its Treatment for Insulin-Dependent Diabetes
http://finance.yahoo.com/news/nuvilex-announces-formation-diabetes-consortium-133000256.html
COCP - Cocrystal Pharma and RFS Pharma Merge to Create Advanced Antiviral Development Organization
http://www.nasdaq.com/press-release/cocrystal-pharma-and-rfs-pharma-merge-to-create-advanced-antiviral-development-organization-20141125-00655#ixzz3K5wTNXYtCocrystal
Last Call NVLX...In the very near term, the comprehensive scientific news of the preclinical study will become evident. Nuvilex and their team of highly qualified medical scientists are shifting the medical paradigm for targeted prodrug delivery in a measured and calculated manner. Patients will soon reap benefits. Stockholders will also. GLTA
Nuvilex Announces Preliminary Data From Preclinical Study of Effects of Its Pancreatic Cancer Treatment on Ascites Fluid Formation
"Preliminary data analysis suggests that treatment with Nuvilex's live-cell encapsulation technology, Cell-in-a-Box® plus ifosfamide, produces a significant survival advantage as compared to non-treated control animals. Nuvilex's treatment appears to be at least as good as cisplatin, the current standard of care for ovarian cancer. However, when the encapsulated cells plus ifosfamide were used in conjunction with cisplatin, the survival rate was greatly enhanced."
http://www.nasdaq.com/press-release/nuvilex-announces-preliminary-data-from-preclinical-study-of-effects-of-its-pancreatic-cancer-20141119-00614
You already know NVLX and COCP. I have CONX but that is tied up in the sale situation. Some speculation that deal will be overturned (27 cents) and maybe some ebola upside. I am not counting on it. Really speculative deal on NPHC, some news today but this is pretty much gambling. Saw something on CLCS but have not yet dug into it. Not bio and currently $1.35 but IMSC looks very interesting. Sorry did not get around to looking at your suggestion AMBS (I think it was) but will get around to it
Joe - what else are you looking at right now?
It's been awhile - I would love to get this board active again. This board was created to bring awareness to all Biotech plays with upcoming catalysts currently trading under $1. Let's get the party started here!
Thoughts on AMBS?
COCP - $0.555 now, + 0.075. WOW
Looks good, thanks Joe
COCP - $0.49. Cocrystal Pharma Develops Novel Ebola Screening Technology
http://finance.yahoo.com/news/cocrystal-pharma-develops-novel-ebola-132554771.html
NVLX-0.22. Nuvilex Secures Worldwide License for Insulin-Producing Cells From University of Technology, Sydney, for Use in Developing Diabetes Treatment
http://finance.yahoo.com/news/nuvilex-secures-worldwide-license-insulin-130000661.html
NVLX $0.21 - Nuvilex, Inc. (otcqb:NVLX) has officially introduced its advanced pancreatic cancer treatment to the U.S. Food and Drug Administration (FDA) in an application asking the agency to grant orphan drug status to its Cell-in-a-Box®/ifosfamide combination for the rare disease.
http://www.marketwatch.com/story/nuvilexs-cancer-treatment-obtaining-fda-orphan-drug-status-would-make-company-attractive-big-pharma-target-2014-10-14
NVLX $0.25- Nuvilex Submits Application for Orphan Drug Designation to the European Medicines Agency for Its Cell-in-a-Box(R) Treatment for Pancreatic Cancer
http://finance.yahoo.com/news/nuvilex-submits-application-orphan-drug-130000183.html
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |